Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B-cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions.

Proprietary or commercial disclosure may be found after the references.

We propose that episodic triggering of abnormal B-cell cytokine responses mediates 'bystander activation' of disease-relevant proinflammatory T cells, resulting in new relapsing MS disease activity. Our findings point to a plausible mechanism for the long-recognized association between infections and new MS relapses, and provide novel insights into B-cell roles in both health and disease, and into mechanisms contributing to therapeutic effects of B-cell depletion in human autoimmune diseases, including MS.

No abstract

Polymer nanocomposites are a promising substitute for energy-storage dielectric materials in pulsed power systems. A barium titanate/polyvinylidenefluoride (BT/PVDF) nanocomposite is one of the most widely studied composite systems due to its comprehensive excellent dielectric properties. As the dielectric response of nanocomposites depends strongly on the size of the fillers, in this study, BT/PVDF nanocomposites with 92.3 nm, 17.8 nm and 5.9 nm BT particle fillers are fabricated to reveal the particle size effect of the fillers on the energy storage performance of the polymer nanocomposites. Owing to the small particle size and good dispersibility of the nanofillers, the nanocomposites with smaller BT particles show more uniform and denser microstructures. Moreover, with the increase of the filler fraction, the dielectric results indicate a breakdown strength enhancement in the nanocomposites with sub-20 nm BT fillers, which is quite different from the nanocomposites with normal fillers, and therefore leads to superior energy storage performance. This study provides experimental evidence for the application of ultrafine nanofillers in the nanocomposite for future energy storage systems.

Human immunodeficiency virus (HIV) has been implicated in neurological complications in developed countries. Developing countries have different viral clades and potentially different genetic and social risks for these complications. Baseline neurological performance measures associated with HIV infection have rarely been available from developing countries. The authors carried our a cross-sectional neurological evaluation of a cohort of community-dwelling treatment-naïve HIV-infected patients and similar control subjects from the same communities in Ethiopia. Blinded evaluation using standardized structured questionnaires and a neurological examination was performed by neurologists and treating physicians trained by an HIV neurology specialist. Quantitative performance measures for cognitive and motor function were employed. Data were analyzed with descriptive statistical methods, standard contingency table methods, and nonparametric methods. HIV-positive and control groups were similar by age, gender, and job site. Participants included 73 HIV-positive and 87 HIV-negative controls. Fingertapping speed in the dominant hand was more poorly performed in HIV positives than negatives (P = .01) and was significantly associated with HIV viral load levels (P = .03). Other quantitative neuropsychiatric tests including timed gait, grooved pegboard, task learning, and animal naming did not show significant differences between the two groups. The overall prevalence of central nervous system (CNS) and/or peripheral nervous system (PNS) disease did not significantly differ in the two populations. HIV patients had slowed fingertapping speed correlating with viral load. Other measures of CNS and/or peripheral nervous performance did not differ from controls. The unanticipated minor evidence of HIV-associated neurocognitive and peripheral nerve deficits in this untreated HIV-positive population invite further investigation.

The switch to a nucleoside-sparing combination antiretroviral regimen (LPV/r + EFV) was associated with significant improvement in limb fat. These results provide additional evidence that nucleoside analogues are important in the progressive limb fat loss that characterizes antiretroviral treatment and that switching medications can significantly improve this complication. This option has to be carefully balanced with the potential to increase serum lipid levels and the trend to increase virologic failure.

No abstract